Clinical progress and pharmacology of small molecule bromodomain inhibitors.

Bromodomains have emerged as an exciting target class for drug discovery over the past decade. Research has primarily focused on the bromodomain and extra terminal (BET) family of bromodomains, which has led to the development of multiple small molecule inhibitors and an increasing number of clinical assets. The excitement centred on the clinical potential of BET inhibition has stimulated intense interest in the broader family and the growing number of non-BET bromodomain chemical probes has facilitated phenotypic investigations, implicating these targets in a variety of disease pathways including cancer, inflammation, embryonic development and neurological disorders.

[1]  Laura E. Jennings,et al.  Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands. , 2014, Future medicinal chemistry.

[2]  A. Palumbo,et al.  Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies , 2014 .

[3]  S. Knapp,et al.  Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains , 2015 .

[4]  C. Vakoc,et al.  A rationale to target the SWI/SNF complex for cancer therapy. , 2014, Trends in genetics : TIG.

[5]  H. Dombret,et al.  A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia , 2014 .

[6]  S. Knapp,et al.  Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance , 2015, Science Advances.

[7]  E. Nicodème,et al.  From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. , 2012, Bioorganic & medicinal chemistry letters.

[8]  David Sidransky,et al.  Genetic and Epigenetic screening for gene alterations of the chromatin‐remodeling factor, SMARCA4/BRG1, in lung tumors , 2004, Genes, chromosomes & cancer.

[9]  J. Bradner,et al.  Abstract A49: Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC) , 2015 .

[10]  A. Palumbo,et al.  O7.3BET-bromodomain (BRD) inhibitor OTX015: Final results of the dose-finding part of a phase I study in hematologic malignancies , 2015 .

[11]  Ming-Ming Zhou,et al.  A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. , 2011, Chemistry & biology.

[12]  Kevin Lee,et al.  Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities. , 2015, Chemistry & biology.

[13]  S. Knapp,et al.  RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain , 2013, Proceedings of the National Academy of Sciences.

[14]  P. Young,et al.  RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist , 2013, PloS one.

[15]  David Newsome,et al.  Gene Dosage–Dependent Embryonic Development and Proliferation Defects in Mice Lacking the Transcriptional Integrator p300 , 1998, Cell.

[16]  M. Höss,et al.  Small molecule inhibitors of bromodomain-acetyl-lysine interactions. , 2015, ACS chemical biology.

[17]  Andrew J. Bannister,et al.  Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. , 2015, Cancer research.

[18]  S. Knapp,et al.  CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses , 2015, Proceedings of the National Academy of Sciences.

[19]  C. Caldas,et al.  p300/CBP and cancer , 2004, Oncogene.

[20]  P. Tak,et al.  Epigenetic mechanisms and drug discovery in rheumatology. , 2015, Clinical medicine.

[21]  Andrew J. Bannister,et al.  Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. , 2016, Journal of medicinal chemistry.

[22]  R. Prinjha,et al.  Progress in the Development of non‐BET Bromodomain Chemical Probes , 2016, ChemMedChem.

[23]  H. Weinmann,et al.  Bromodomains and Their Pharmacological Inhibitors , 2014, ChemMedChem.

[24]  P. P. Sharp,et al.  BET bromodomain inhibitors: a patent review , 2014, Expert opinion on therapeutic patents.

[25]  P. Bamborough,et al.  Fragments in bromodomain drug discovery , 2015 .

[26]  C. Bountra,et al.  Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.

[27]  P. Bamborough,et al.  Discovery and characterization of small molecule inhibitors of the BET family bromodomains. , 2011, Journal of medicinal chemistry.

[28]  S. Knapp,et al.  3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands , 2011, Journal of medicinal chemistry.

[29]  Julien Rossignol,et al.  Machine-assisted synthesis of modulators of the histone reader BRD9 using flow methods of chemistry and frontal affinity chromatography , 2014 .

[30]  J. Manfredi,et al.  Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. , 2006, Chemistry & biology.

[31]  C. Rice,et al.  Suppression of inflammation by a synthetic histone mimic , 2010, Nature.

[32]  Ming-Ming Zhou,et al.  The Bromodomain: A New Target in Emerging Epigenetic Medicine. , 2016, ACS chemical biology.

[33]  F. A. Romero,et al.  Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors. , 2016, Journal of medicinal chemistry.

[34]  A. Caflisch,et al.  Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain. , 2016, Journal of medicinal chemistry.

[35]  M. Cuadros,et al.  SWI/SNF proteins as targets in cancer therapy , 2014, Journal of Hematology & Oncology.

[36]  P. Bamborough,et al.  Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. , 2013, Journal of medicinal chemistry.

[37]  B. Quesnel,et al.  Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies , 2016, Clinical Pharmacokinetics.

[38]  G. Bifulco,et al.  9H-Purine Scaffold Reveals Induced-Fit Pocket Plasticity of the BRD9 Bromodomain , 2015, Journal of medicinal chemistry.

[39]  C. Petosa,et al.  Bromodomains: Structure, function and pharmacology of inhibition. , 2016, Biochemical pharmacology.

[40]  S. Knapp,et al.  Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains , 2014, Journal of the American Chemical Society.

[41]  Ramzi F Sweis,et al.  Target (In)Validation: A Critical, Sometimes Unheralded, Role of Modern Medicinal Chemistry. , 2015, ACS medicinal chemistry letters.

[42]  T. Matt.  Transcriptional control of the inflammatory response: a role for the CREB-binding protein (CBP). , 2002, Acta medica Austriaca.

[43]  Mark E Bunnage,et al.  Target validation using chemical probes. , 2013, Nature chemical biology.

[44]  Parantu K. Shah,et al.  The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. , 2015, Cancer research.

[45]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[46]  I. Flinn,et al.  BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study , 2015 .

[47]  P. L. Bergsagel,et al.  The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound. , 2014, Cell reports.

[48]  R. Elkon,et al.  BRD7 is a candidate tumour suppressor gene required for p53 function , 2010, Nature Cell Biology.

[49]  S. Knapp,et al.  LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor** , 2015, Angewandte Chemie.

[50]  Ming-Ming Zhou,et al.  Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. , 2005, Journal of the American Chemical Society.